Comparative Pharmacology
Head-to-head clinical analysis: DIAMOX versus DICHLORPHENAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIAMOX versus DICHLORPHENAMIDE.
DIAMOX vs DICHLORPHENAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.
Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.
250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure
25-50 mg orally twice daily.
None Documented
None Documented
10-15 hours; prolonged to up to 24+ hours in renal impairment; clinical context: requires twice-daily dosing for continuous effect.
Terminal elimination half-life of 2-4 hours; increased in renal impairment, up to 12-24 hours in severe insufficiency.
Renal; 70-100% unchanged by tubular secretion and passive reabsorption; pH-dependent; alkaline urine increases elimination.
Primarily renal via tubular secretion; 50-70% excreted unchanged in urine; minor biliary/fecal elimination (<20%).
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor